Mersana Therapeutics Inc
MRSN28.920USD
-0.020-0.07%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
144.56MMarket Cap
LossP/E TTM
More Details of Mersana Therapeutics Inc Company
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is a cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).
Mersana Therapeutics Inc Info
Ticker SymbolMRSN
Company nameMersana Therapeutics Inc
IPO dateJun 28, 2017
CEOHuber (Martin H)
Number of employees102
Security typeOrdinary Share
Fiscal year-endJun 28
Address840 Memorial Dr
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02139
Phone16174980020
Websitehttps://www.mersana.com/
Ticker SymbolMRSN
IPO dateJun 28, 2017
CEOHuber (Martin H)
Company Executives of Mersana Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
23.93K
--
Dr. Timothy B. Lowinger, Ph.D.
Dr. Timothy B. Lowinger, Ph.D.
Senior Vice President, Chief Science and Technology Officer
Senior Vice President, Chief Science and Technology Officer
10.31K
+0.55%
Mr. Brian Deschuytner
Mr. Brian Deschuytner
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Chief Financial Officer, Chief Operating Officer, Senior Vice President
4.86K
+7.10%
Dr. Mohan Bala, Ph.D.
Dr. Mohan Bala, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
2.93K
+6.28%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Independent Director
Independent Director
663.00
--
Ms. Alejandra V. Carvajal, J.D.
Ms. Alejandra V. Carvajal, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Dr. Andrew A. F. Hack, M.D., Ph.D.
Dr. Andrew A. F. Hack, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Martin H. Huber, M.D.
Dr. Martin H. Huber, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Anna Protopapas
Ms. Anna Protopapas
Director
Director
--
--
Dr. Willard H. Dere, M.D.
Dr. Willard H. Dere, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Chairman of the Board
Independent Chairman of the Board
23.93K
--
Dr. Timothy B. Lowinger, Ph.D.
Dr. Timothy B. Lowinger, Ph.D.
Senior Vice President, Chief Science and Technology Officer
Senior Vice President, Chief Science and Technology Officer
10.31K
+0.55%
Mr. Brian Deschuytner
Mr. Brian Deschuytner
Chief Financial Officer, Chief Operating Officer, Senior Vice President
Chief Financial Officer, Chief Operating Officer, Senior Vice President
4.86K
+7.10%
Dr. Mohan Bala, Ph.D.
Dr. Mohan Bala, Ph.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
2.93K
+6.28%
Mr. Lawrence M. (Larry) Alleva, CPA
Mr. Lawrence M. (Larry) Alleva, CPA
Independent Director
Independent Director
663.00
--
Ms. Alejandra V. Carvajal, J.D.
Ms. Alejandra V. Carvajal, J.D.
Senior Vice President, Chief Legal Officer
Senior Vice President, Chief Legal Officer
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
3.06M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nextech Invest, Ltd.
9.66%
Alamea Verwaltungs GmbH
8.60%
Bain Capital Life Sciences Investors, LLC
6.93%
The Vanguard Group, Inc.
6.05%
Schonfeld Strategic Advisors LLC
5.47%
Other
63.28%
Shareholders
Shareholders
Proportion
Nextech Invest, Ltd.
9.66%
Alamea Verwaltungs GmbH
8.60%
Bain Capital Life Sciences Investors, LLC
6.93%
The Vanguard Group, Inc.
6.05%
Schonfeld Strategic Advisors LLC
5.47%
Other
63.28%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.20%
Hedge Fund
22.97%
Investment Advisor/Hedge Fund
6.52%
Research Firm
2.49%
Individual Investor
1.67%
Venture Capital
1.04%
Family Office
0.32%
Bank and Trust
0.04%
Other
30.75%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
299
3.05M
61.05%
-2.62M
2025Q2
344
3.57M
71.71%
-3.19M
2025Q1
381
91.14M
73.20%
-85.10M
2024Q4
376
108.41M
87.04%
-80.71M
2024Q3
381
121.20M
99.04%
-61.95M
2024Q2
378
118.97M
97.46%
-69.30M
2024Q1
377
122.29M
100.13%
-59.89M
2023Q4
366
116.96M
97.07%
-50.97M
2023Q3
372
116.93M
97.32%
-45.36M
2023Q2
374
120.10M
105.19%
-2.78M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nextech Invest, Ltd.
482.69K
9.67%
--
--
Jun 30, 2025
Bain Capital Life Sciences Investors, LLC
346.55K
6.94%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
307.14K
6.15%
-27.98K
-8.35%
Jun 30, 2025
Schonfeld Strategic Advisors LLC
226.95K
4.55%
-77.61K
-25.48%
Jun 30, 2025
683 Capital Management LLC
79.60K
1.59%
+13.60K
+20.61%
Jun 30, 2025
Rock Springs Capital Management LP
152.59K
3.06%
--
--
Jun 30, 2025
Acadian Asset Management LLC
118.21K
2.37%
-1.38K
-1.15%
Jun 30, 2025
SilverArc Capital Management, LLC
125.14K
2.51%
+1.60K
+1.29%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
142.35K
2.85%
-155.10K
-52.14%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
State Street SPDR S&P Biotech ETF
0%
Direxion Daily S&P Biotech Bull 3X Shares
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Hedge Replication ETF
0%
Pacer WealthShield ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Global X Russell 2000 Covered Call ETF
0%
Avantis US Equity ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
View more
State Street SPDR S&P Biotech ETF
Proportion0%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Pacer WealthShield ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Avantis US Equity ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jul 24, 2025
Merger
25→1
Date
Type
Ratio
Jul 24, 2025
Merger
25→1
FAQs
Who are the top five shareholders of Mersana Therapeutics Inc?
The top five shareholders of Mersana Therapeutics Inc are:
Nextech Invest, Ltd. holds 482.69K shares, accounting for 9.67% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 346.55K shares, accounting for 6.94% of the total shares.
The Vanguard Group, Inc. holds 307.14K shares, accounting for 6.15% of the total shares.
Schonfeld Strategic Advisors LLC holds 226.95K shares, accounting for 4.55% of the total shares.
683 Capital Management LLC holds 79.60K shares, accounting for 1.59% of the total shares.
Nextech Invest, Ltd. holds 482.69K shares, accounting for 9.67% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 346.55K shares, accounting for 6.94% of the total shares.
The Vanguard Group, Inc. holds 307.14K shares, accounting for 6.15% of the total shares.
Schonfeld Strategic Advisors LLC holds 226.95K shares, accounting for 4.55% of the total shares.
683 Capital Management LLC holds 79.60K shares, accounting for 1.59% of the total shares.
What are the top three shareholder types of Mersana Therapeutics Inc?
The top three shareholder types of Mersana Therapeutics Inc are:
Nextech Invest, Ltd.
Alamea Verwaltungs GmbH
Bain Capital Life Sciences Investors, LLC
Nextech Invest, Ltd.
Alamea Verwaltungs GmbH
Bain Capital Life Sciences Investors, LLC
How many institutions hold shares of Mersana Therapeutics Inc (MRSN)?
As of 2025Q3, 299 institutions hold shares of Mersana Therapeutics Inc, with a combined market value of approximately 3.05M, accounting for 61.05% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -10.66%.
What is the biggest source of revenue for Mersana Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Mersana Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
